Panibinostat Shows Promise in Treating DIPG in Preclinical Testing
In May 2015, researchers released the results of a study conducted on the DIPG cell lines and DIPG-infected mice. This study looked at 83 different potential chemotherapy drugs, and identified one of them – panobinostat – as potentially effective in treating DIPG. Panobinostat is a “histone deacetylase inhibitor,” which means that it affects that way histone-wrapped DNA is modified reversing some of the abnormal gene expression pattern of DIPG cells. Given that most DIPG tumors also have other mutations and abnormalities, panobinostat is not expected to cure any DIPG patients by itself, but doctors and researchers are optimistic that it could provide an effective treatment when used in combination with other drugs. There are not yet any clinical trial using panobinostat, but that will likely change in the next few months as trials are expected to begin soon.